Aurobindo Pharma hits lower circuit after FDA reopens investigation in Unit IV
Updated : February 24, 2020 09:58 AM IST
Aurobindo Pharma hit the lower circuit on Monday after US FDA rescinded the 'Voluntary Action Indicated' (VAI) letter for the company's Unit-IV within three days of its issuance.
The company also said that that the inspection is still open, with the status under review.
Post the announcement, the stock plunged 10 percent to Rs 539.60 per share on BSE.